FDA expects to issue new standards soon for tracking drug products through the supply chain, which could foreshadow congressional moves to strengthen the system intended to fight drug adulteration and counterfeiting.
According to Ilisa Bernstein, acting director of the CDER Office of Compliance, the standards are “pretty far along” in development...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?